Page last updated: 2024-09-04

docetaxel anhydrous and pyrimidinones

docetaxel anhydrous has been researched along with pyrimidinones in 2 studies

Compound Research Comparison

Studies (docetaxel anhydrous)	Trials (docetaxel anhydrous)	Recent Studies (post-2010) (docetaxel anhydrous)	Studies (pyrimidinones)	Trials (pyrimidinones)	Recent Studies (post-2010) (pyrimidinones)
12,110	3,216	6,920	6,059	604	2,692

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ahn, MJ; Baas, P; Blumenschein, GR; Cadranel, J; De Pas, T; Dunphy, F; Hanna, NH; Jänne, PA; Kim, DW; Kim, JH; Kim, SW; Mazieres, J; Planchard, D; Puski, A; Rappold, E; Redhu, S; Smit, EF; Udud, K; Wu, FS	1
Balaji, U; Conway, W; Eslinger, C; Knudsen, ES; McMillan, E; Mills, GB; O'Reilly, EM; Posner, B; Witkiewicz, AK	1

Trials

1 trial(s) available for docetaxel anhydrous and pyrimidinones

Article	Year
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†. Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:5 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Pyridones; Pyrimidinones; Signal Transduction; Taxoids; Time Factors; Treatment Outcome	2015

Article

Year

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.

Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:5

Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Pyridones; Pyrimidinones; Signal Transduction; Taxoids; Time Factors; Treatment Outcome

2015

Other Studies

1 other study(ies) available for docetaxel anhydrous and pyrimidinones

Article	Year
Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer. Cell reports, 2016, 08-16, Volume: 16, Issue:7 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Dasatinib; Docetaxel; Drug Resistance, Neoplasm; Everolimus; Exome; Humans; Mice; Models, Genetic; Models, Statistical; Pancreatic Neoplasms; Precision Medicine; Prognosis; Pyridones; Pyrimidinones; Taxoids; Xenograft Model Antitumor Assays	2016

Article

Year

Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer.

Cell reports, 2016, 08-16, Volume: 16, Issue:7

Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Dasatinib; Docetaxel; Drug Resistance, Neoplasm; Everolimus; Exome; Humans; Mice; Models, Genetic; Models, Statistical; Pancreatic Neoplasms; Precision Medicine; Prognosis; Pyridones; Pyrimidinones; Taxoids; Xenograft Model Antitumor Assays

2016